Literature DB >> 3717930

Hemodialysis clearance of metronidazole and its metabolites.

A H Lau, C W Chang, S Sabatini.   

Abstract

Metronidazole is now being used with increasing frequency for various infectious conditions in patients with renal failure. It is commonly administered to septic patients who have developed acute renal failure requiring hemodialysis. The hemodialysis clearances of metronidazole and its metabolites were evaluated in nine renal failure patients on maintenance hemodialysis. The mean +/- standard deviation clearance and the extraction ratio were 106.9 +/- 16.3 ml/min and 0.65 +/- 0.08, respectively, when regenerated cellulose dialysis membrane was used. The clearance and the extraction ratio with the use of cuprophan membrane were 72.1 +/- 17.3 ml/min and 0.44 +/- 0.12, respectively. The clearances and extraction ratios for the metabolites were similar to those of the parent drug. For both metronidazole and the hydroxy metabolite, the clearance and the extraction ratio demonstrated a statistically significant difference between the regenerated cellulose membrane and the cuprophan membrane. In summary, metronidazole and its metabolites were found to be highly dialyzable with different clearances depending on the specific type of membrane used. However, owing to the relatively wide therapeutic index of the drug, dosage supplementation may be necessary only in seriously ill patients to ensure therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717930      PMCID: PMC176383          DOI: 10.1128/AAC.29.2.235

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Absorption and excretion of metronidazole. I. Serum concentration and urinary excretion after oral administration.

Authors:  P O KANE; J A McFADZEAN; S SQUIRES; A J KING; C S NICOL
Journal:  Br J Vener Dis       Date:  1961-12

2.  Use of high-pressure liquid chromatography to determine plasma levels of metronidazole and metabolites after intravenous administration.

Authors:  L A Wheeler; M De Meo; M Halula; L George; P Heseltine
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

3.  Metronidazole.

Authors:  S M Finegold
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

4.  Removal of metronidazole by haemodialysis.

Authors:  R Gabriel; C M Page; J Collier; G W Houghton; R Templeton; P S Thorne
Journal:  Br J Surg       Date:  1980-08       Impact factor: 6.939

5.  Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study.

Authors:  A F Roux; E Moirot; B Delhotal; J A Leroy; G P Bonmarchand; G Humbert; B Flouvat
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

6.  Mental confusion in a patient treated with metronidazole--a concentration-related effect?

Authors:  J J Schentag; J A Ziemniak; J M Greco; M Rainstein; R J Buckley
Journal:  Pharmacotherapy       Date:  1982 Nov-Dec       Impact factor: 4.705

7.  Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D R Guay; R C Meatherall; H Baxter; W R Jacyk; B Penner
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections.

Authors:  F P Tally; C E Sullivan
Journal:  Pharmacotherapy       Date:  1981 Jul-Aug       Impact factor: 4.705

Review 9.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  9 in total
  6 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Prevalence of intestinal parasite infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis.

Authors:  V Fallah Omrani; Sh Fallahi; A Rostami; A Siyadatpanah; Gh Barzgarpour; S Mehravar; F Memari; F Hajialiani; Z Joneidi
Journal:  Infection       Date:  2015-04-14       Impact factor: 3.553

Review 4.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

5.  Metronidazole-induced encephalopathy in a patient with liver cirrhosis.

Authors:  Hyeong Cheol Cheong; Taek Geun Jeong; Young Bum Cho; Bong Joon Yang; Tae Hyeon Kim; Haak Cheoul Kim; Eun-Young Cho
Journal:  Korean J Hepatol       Date:  2011-06

Review 6.  Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.

Authors:  A Mary Vilay; Mariann D Churchwell; Bruce A Mueller
Journal:  Crit Care       Date:  2008-11-12       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.